Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2025-12-27 @ 12:39 PM
Study NCT ID:
NCT00396760
Status:
UNKNOWN
Last Update Posted:
2006-11-07
First Post:
2006-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006470', 'term': 'Hemorrhage'}], 'ancestors': [{'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007611', 'term': 'Aprotinin'}, {'id': 'D014148', 'term': 'Tranexamic Acid'}], 'ancestors': [{'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D003509', 'term': 'Cyclohexanecarboxylic Acids'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 220}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2005-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2006-11', 'completionDateStruct': {'date': '2006-07'}, 'lastUpdateSubmitDate': '2006-11-06', 'studyFirstSubmitDate': '2006-11-06', 'studyFirstSubmitQcDate': '2006-11-06', 'lastUpdatePostDateStruct': {'date': '2006-11-07', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-11-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '24 hours postoperative drainage blood loss'}, {'measure': 'incidence of allogeneic blood transfusion'}], 'secondaryOutcomes': [{'measure': 'activation of fibrinolysis and hemostasis'}, {'measure': 'impairment of renal function'}]}, 'conditionsModule': {'keywords': ['cardiac surgery', 'blood transfusion', 'antifibrinolytics', 'aprotinin', 'tranexamic acid'], 'conditions': ['Bleeding and Cardiac Surgery', 'Allogeneic Blood Transfusion', 'Aortic Valve Replacement', 'Coronary Artery Bypass Graft Surgery']}, 'referencesModule': {'references': [{'pmid': '15591329', 'type': 'BACKGROUND', 'citation': "Diprose P, Herbertson MJ, O'Shaughnessy D, Deakin CD, Gill RS. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth. 2005 Mar;94(3):271-8. doi: 10.1093/bja/aei044. Epub 2004 Dec 10."}, {'pmid': '11279735', 'type': 'BACKGROUND', 'citation': "Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;(1):CD001886. doi: 10.1002/14651858.CD001886."}, {'pmid': '17056936', 'type': 'BACKGROUND', 'citation': 'Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, Spiess BD, Nadel A. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg. 2006 Nov;103(5):1082-8. doi: 10.1213/01.ane.0000238447.74029.f5.'}, {'pmid': '17056935', 'type': 'BACKGROUND', 'citation': 'Dietrich W, Busley R, Kriner M. High-dose aprotinin in cardiac surgery: is high-dose high enough? An analysis of 8281 cardiac surgical patients treated with aprotinin. Anesth Analg. 2006 Nov;103(5):1074-81. doi: 10.1213/01.ane.0000238446.30034.c8.'}, {'pmid': '21127274', 'type': 'DERIVED', 'citation': 'Lison S, Dietrich W, Braun S, Boehm J, Schuster T, Englhard A, Perchuc A, Spannagl M, Busley R. Enhanced thrombin generation after cardiopulmonary bypass surgery. Anesth Analg. 2011 Jan;112(1):37-45. doi: 10.1213/ANE.0b013e3181fc6df0. Epub 2010 Dec 2.'}, {'pmid': '18931201', 'type': 'DERIVED', 'citation': 'Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.'}]}, 'descriptionModule': {'briefSummary': 'The hypothesis of this study is that the antifibrinolytic drugs aprotinin and tranexamic acid equally influence bleeding tendency and transfusion requirement in patients undergoing first time cardiac procedures with a low risk of increased postoperative bleeding.Only patients undergoing first time CABG or first time aortic valve replacement are included in this study.', 'detailedDescription': 'Excessive bleeding during and after cardiac surgery is a serious complication. It exposes patients to the risk of allogeneic blood transfusion or other blood products and the risk of mediastinal re-exploration.Antifibrinolytic drugs like aprotinin and tranexamic acid are proven to reduce bleeding tendency and transfusion requirement in cardiac surgery. The efficacy of these drugs is proven, especially for the unspecific proteinase inhibitor aprotinin, however, there are concerns about the safety and the high costs of this drug. There are only limited head-to-head comparisons of these two drugs.\n\nIn this double-blind, prospective, controlled study the efficacy of aprotinin and tranexamic acid is compared. Primary outcome is the 24 hours postoperative drainage blood loss and the percentage of patients requiring allogeneic blood transfusion during the hospital stay. Subgroups of patients undergoing CABG surgery or aortic valve replacement are predefined for combined and separate data analysis.The power of the study is calculated for this subgroup-analysis.\n\nSecondary outcome measurements are molecular marker of activation of hemostasis up to the 5th postoperative day.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* informed consent\n* Patients undergoing primary CABG or Aortic valve replacement surgery\n\nExclusion Criteria:\n\n* Previous sternotomy\n* OPCAB surgery\n* urgent/emergency operation\n* Coumadin treatment\n* previous aprotinin exposure\n* preoperative renal impairment (Creatinine \\> 2 mg/dL)\n* patients refusing blood transfusions\n* no informed consent'}, 'identificationModule': {'nctId': 'NCT00396760', 'briefTitle': 'Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery', 'organization': {'class': 'OTHER', 'fullName': 'German Heart Center'}, 'officialTitle': 'The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization', 'orgStudyIdInfo': {'id': '1172/04'}}, 'armsInterventionsModule': {'interventions': [{'name': 'aprotinin or tranexamic acid', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': '80636', 'city': 'Munich', 'state': 'Munich', 'country': 'Germany', 'facility': 'German Heart Center Munich', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}], 'overallOfficials': [{'name': 'Wulf Dietrich, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Department of Anesthesiology, German Heart Center Munich'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'German Heart Center', 'class': 'OTHER'}}}}